Company news

Wave Life Sciences Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 3, 2025

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

February 24, 2025

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

February 5, 2025

Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

January 12, 2025

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

December 22, 2024

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

December 15, 2024

Wave Life Sciences to Present at Jefferies London Healthcare Conference

November 14, 2024

Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

November 3, 2024

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

October 29, 2024

Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

October 15, 2024

Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

October 15, 2024

Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 30, 2024

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

September 29, 2024

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

September 24, 2024

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

September 23, 2024

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

September 23, 2024

Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

August 11, 2024

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

August 7, 2024

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

July 31, 2024

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease

June 24, 2024

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

June 11, 2024

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference

May 29, 2024

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024

Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

May 8, 2024

Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference

May 6, 2024

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024

May 1, 2024

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)

April 29, 2024

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

April 22, 2024

Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 5, 2024

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

February 27, 2024

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

February 26, 2024

Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones

January 7, 2024

Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

December 14, 2023

Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares

December 6, 2023

Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency

December 5, 2023

Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference

November 21, 2023

Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023

Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023

November 2, 2023

Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

September 27, 2023

Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference

September 24, 2023

Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”

September 4, 2023

Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

August 2, 2023

Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023

July 26, 2023

Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes

June 25, 2023

Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

May 22, 2023

Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting

May 15, 2023

Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 97 decks. Every deck is listed under its year.